Month: May 2020

RESEARCH TRIANGLE PARK, N.C., May 29, 2020 (GLOBE NEWSWIRE) — Charles & Colvard, Ltd. (Nasdaq: CTHR), (the “Company”), the original and leading worldwide source of created moissanite, announced today that its Board of Directors appointed Don O’Connell to the position of President and Chief Executive Officer, effective June 1, 2020. He will also join the Company’s Board of Directors.Mr. O’Connell, who most recently served as Chief Operating Officer and Senior Vice President, Supply Chain of Charles & Colvard, succeeds Suzanne Miglucci, who resigned as President and CEO and as a member of the Board of Directors, effective June 1, 2020.Neal Goldman, Chairman of the Board of Directors of Charles & Colvard, said, “Even in these changing times, we believe the market opportunity continues to exist for our gemstones...

BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology (ASCO20) Annual Meeting. NC318 is a monoclonal antibody targeting Siglec-15 (S15), a novel immunomodulatory protein that is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells.“Because this is a trial in progress with limited samples, we cannot draw definitive conclusions, but we believe these early biomarker data provide additional evidence...

A poster presentation (abstract 3025) demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II studyAn abstract accepted for publication (abstract e15018) presents pre-clinical data demonstrating how a CD38 knock-out of off-the-shelf FC21-NK cells limits NK cell fratricide and enhances the overall activity against multiple myeloma cells in presence of an anti-CD38 antibodyAn additional poster presentation (abstract TPS7562) describes the clinical trial for the first-in-man assessment of off-the-shelf FC21-NK cells derived from universal allogeneic donors in R/R AML and MDSAmsterdam, The Netherlands, May 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, announces that...

REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)Heidelberg, Germany, May 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today shared details of its AFM13 REDIRECT clinical trial design and rationale at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, being held in virtual format on May 29-31, 2020.AFM13 is a first-in-class innate cell engager that induces specific and selective killing of CD30-positive tumor cells by engaging and activating NK cells and macrophages thereby leveraging the power of the innate immune system....

– First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate, Directed Against CD71: A Previously Undruggable Target –– Data Updates for CX-2009 Support Phase 2 Investigations in Breast Cancer –– Favorable Tolerability Profile Demonstrated for Anti-PD-L1 and Anti-CTLA-4 Probody Therapeutics –– Company to Host Webcast Today, May 29, 2020 at 5:00 p.m. ET/ 2:00 p.m. PT –SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the availability of oral and poster presentations at the American Society of Clinical Oncology’s (ASCO) ASCO20...

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up36.4% Overall Response Rate (ORR) MaintainedSAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program.“We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program,” said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “The median duration of response has not been reached at 18.7 months of study follow up supporting...

VANCOUVER, British Columbia, May 29, 2020 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”) (TSX: CFF) announced today that it will further extend the temporary curtailment of operations at its Mackenzie, British Columbia sawmill for an additional five weeks to July 6, 2020, as the impacts of the COVID-19 pandemic continue to adversely affect global demand for forest products. During this time, Conifex will also work with relevant participants towards securing a more affordable sawlog supply capable of supporting the sawmill’s re-start as planned.The curtailment is not expected to impact bioenergy operations.Conifex will continue to closely monitor evolving market conditions, customer demand and the global COVID-19 response while prioritizing employee health and safety considerations.For further information, please contact:About...